# Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

> **NCT03366324** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Wuhan Sian Medical Technology Co., Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- B Cell Lymphoma

## Interventions

- **GENETIC:** Second generation CAR-T cells
- **PROCEDURE:** Hematological stem cell transplantation

## Key facts

- **NCT ID:** NCT03366324
- **Lead sponsor:** Wuhan Sian Medical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05-01
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366324, "Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03366324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*